SKYEPHARMA PLC
Form 6-K
August 01, 2006

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_____

For Immediate Release **1 August, 2006**

Critical Therapeutics Files Controlled Release Formulation of Zileuton

LONDON, UK, 1 August 2006 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces that its partner Nasdaq: CRTX) has submitted a New Drug Application to the US Food & Drug Administration for a c oral anti-inflammatory drug zileuton for asthma in adults and children aged 12 years or older. taken twice a day whereas Zyflo®, the currently marketed version of zileuton, has the drawback of

A four times a day immediate-release version of zileuton was marketed by Abbott Laboratories (" tablets). SkyePharma developed a controlled-release formulation of zileuton, using its Geoma completed Phase III development in asthma with this product. CTI acquired the rights to zileuto SkyePharma has collaborated with CTI on the further development of this formulation. SkyePharma on CTI's sales of the controlled-release formulation of zileuton and will also manufacture the France.

Frank Condella, Chief Executive of SkyePharma, said: "We are pleased that this successful coll in the filing of this version of zileuton, another example of the power of our Geomatrix t product to reach the market in the second half of next year when it will become another source for SkyePharma."

For further information please contact:

SkyePharma PLC **+44 207 491 1777**
Frank Condella, Chief Executive Officer
Peter Laing, Director of Corporate Communications **44 207 491 5124**
Sandra Haughton, US Investor Relations **+1 212 753 5780**

Buchanan Communications **+44 207 466 5000**
Tim Anderson / Mark Court / Rebecca Skye Dietrich

About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery techn and more effective drug formulations. There are now twelve approved products incorporating SkyePh oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities www.skyepharma.com.

About Critical Therapeutics
Critical Therapeutics, Inc. is a biopharmaceutical company focused on critical care medicin development and commercialization of novel therapies for the treatment of acute trauma, cardio inflammatory illness. The Company is headquartered in Cambridge, Massachusetts. More inf www.crtx.com.

About zileuton
Zileuton is a highly potent oral anti-inflammatory drug. It works by inhibiting the enzyme 5- involved in the formation of leukotrienes, is a key part of the inflammatory cascade that follo this enzyme therefore helps minimise bronchoconstriction and mucus secretion in asthma. In zileuton was shown to bring the greatest benefit to those with the most severe disease. Zileuto asthma symptoms but chronic treatment with zileuton allows reduction of other therapies such as side-effects.

Certain statements in this news release are forward-looking statements and are made in reliance o U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectation statements are reasonable, it can give no assurance that these expectations will materialize. Bec risks and uncertainties, actual results may vary significantly from those expressed or implied by based upon a number of factors, which are described in SkyePharma's 20-F and other documents on f cause differences between actual results and those implied by the forward-looking statements cont without limitation, risks related to the development of new products, risks related to obtaining for existing, new or expanded indications of existing and new products, risks related to SkyePhar on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to maintain or expand market share in the face of changes in customer requirements, competition and to regulatory compliance, the risk of product liability claims, risks related to the ownership an risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to re

forward-looking statement to reflect events or circumstances after the date of this release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: August 1, 2006